Cath Eberlein

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 257 citations · Full text

Covalent Inhibitors, Drug Target, Thiol Reactivity +19

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib

Michael G. Rolf, Jon Curwen, Margaret H. Veldman-Jones et al. · Pharmacology Research & Perspectives · 2015 · 108 citations · Full text

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>

David W. Jenkins, Sarah J. Ross, Margaret H. Veldman-Jones et al. · Molecular Cancer Therapeutics · 2012 · 51 citations

Angiogenesis, Novel Therapy, Medicine +13

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

Matthew J. Martin, Cath Eberlein, Molly A. Taylor et al. · Oncotarget · 2016 · 43 citations · Full text

Cancer Biology, Suppresses Glycolysis, Tumor Biology +17